Navigation Links
ACR statement on cancer study regarding patient anxiety from CT lung cancer screening
Date:7/25/2014

Anxiety regarding inconclusive cancer screening test results among some patients is real and is only natural. However, as evidenced by Gareen et al, published July 25 in Cancer, the incidence and effects of anxiety associated with false positive or other results of computed tomography (CT) lung cancer screening exams are far less than claimed by some in the medical community.

"Unsubstantiated claims of systemic and harmful patient anxiety should now be put to rest and not continue to delay implementation of CT lung cancer screening programs or Medicare coverage for these tests. It is clear that the lifesaving benefit of these exams in high-risk patients far outweighs any downside," said Ella A. Kazerooni, MD, chair of the American College of Radiology Lung Screening Committee.

Gareen et al found that patients who had an abnormal finding on a lung cancer screening test did not experience more anxiety or reduced quality of life than those who were screened and found to be cancer-free. Imaging experts (researchers and clinicians) and allied professionals continue to work to reduce the number of false-positive exams that patients experience and ensure that follow-up exams are as minimally invasive as possible. Physicians also continue to refine the reporting process to ensure that patients receive results as quickly as possible.

Primary National Lung Screening Trial (NLST) results showed that screening high-risk patients for lung cancer using low-dose computed tomography (CT) scans significantly reduced lung cancer deaths. The test is at least as cost-effective as other major cancer screening programs and even automobile seatbelts and airbags. In December 2013, the United States Preventive Services Task Force (USPSTF) recommended annual CT lung cancer screening for high-risk patients. Under the Affordable Care Act, private insurers are required to begin covering this service starting Jan. 1, 2015. However, Medicare is not required to follow USPSTF recommendations. CMS will make its final coverage decision in February 2015.

Significant lung cancer screening infrastructure continues to grow. The College created the ACR Lung Cancer Screening Center program, to help certify that these lifesaving exams are provided in a safe, effective manner. The ACR also launched the first edition of Lung-RADS, a quality assurance tool designed to standardize lung cancer screening CT reporting and management recommendations, reduce confusion in lung cancer screening CT interpretations and facilitate outcome monitoring.

"For the first time, we can save thousands of people each year from the nation's leading cancer killer. Medicare coverage of these lifesaving exams would provide seniors with ready access to this care and help the medical community save lives," said Kazerooni.


'/>"/>
Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Related medicine news :

1. AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014
2. Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation
3. Journal Maturitas publishes position statement on management of uterine fibroids
4. Maturitas publishes position statement on management of vertebral osteoporotic fracture
5. Elseviers Maturitas publishes position statement on menopause for medical students
6. Diversity Focus Issues Statement of Purpose
7. The Association for Molecular Pathology releases position statement on LDTs
8. Contra-culture Miami Plastic Surgeon Releases Public Statement “I Don’t Want To Be Your Plastic Surgeon”
9. New York Bicycle Accident Lawyer Adnan Munawar Issues a Statement on Alleged CitiBike Safety Hazard
10. Searchen Releases Statement on Celebrity and Athletic Endorsement Study
11. SEARCHEN® Releases Statement on Report of 1,000 Percent Mobile Conversion Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and ... in Mystic, CT. Covering the process and maintenance strategies of gum grafting and ... periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists in ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: